Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats

Journal of Biomedical Research

Volumn 25, Issue 6, 2011, Pages 411-417

  Rao, Ravi Prakash ^a   Singh, Ansima ^b   Jain, Arun K ^c   Srinivasan, Bhartu Parsharthi ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

^c SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

Diabetic nephropathy; Peroxisome proliferator activated receptors (PPARs); Transforming growth factor 1 (TGF 1); Tumor necrosis factor (TNF ); Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; FIBRONECTIN; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCOSE; INSULIN; PROTEIN; STREPTOZOCIN; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; KIDNEY STRUCTURE; MALE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY; URINARY EXCRETION;

EID: 84455172351     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(11)60054-7     Document Type: Article

References (38)

1. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C Epidemiology of type 2 diabetes: Indian scenario. Ind J Med Res 2007, 125:217-230.
2. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabe-tologia 1983, 25:496-501.
3. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985, 78:785-794.
4. Rossing P, Rossing K, Jacobsen P, Parving HH Un-changed incidence of diabetic nephropathy in IDDM patients. Diabetes 1995, 44:739-743.
5. Ballard DJ, Humphrey LL, Melton LJ, Frohnert PP, Chu PC, Ofallon WM, et al. Epidemiology of persistent pro-teinuria in type 2 diabetes mellitus. Population based study in Rochester, Minnesota. Diabetes 1988, 37:405-412.
6. Kunzelman CL, Knowlen WC, Pettitt DJ, Bennett PH Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int 1989, 35:681-687.
7. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of com-plications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 12:837-853.
8. Diabetes control and complications trial research group The effect of intensive treatment of diabetes on the de-velopment and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
9. Balakumar P, Chakkarwar VA, Kumar V, Jain A, Reddy J, Singh M Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 2008, 9:189-195.
10. Hasslacher C, Ritz E, Wahl P Similar risks of nephropa-thy in type 1 or type 2 diabetes mellitus. Nephrol Dial Transpl 1989, 4:859-863.
11. Cooper ME Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998, 352:213-219.
12. Caramori ML, Mauer M Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12:273-282.
13. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal dis-ease with special reference to microalbuminuria. Lancet 1995, 346:1080-1084.
14. Remuzzi G, Benigni A, Remuzzi A Mechanisms of pro-gression and regression of renal lesions of chronic neph-ropathies and diabetes. J Clin Invest 2006, 116:288-296.
15. Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, et al. Peroxisome Proliferator-Activated Receptor α/γ dual agonist Tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007, 56:2036-2045.
16. Mao Z, Ong ACM Peroxisome Proliferator-Activated Receptor gamma agonists in kidney disease- future promise, present fears. Nephron Clin Pract 2009, 112:c230-c241.
17. Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002, 25(7):1251-1252.
18. Thomas S, Viberti G Diabetic nephropathy. Medicine 2006, 34(3):83-86.
19. Ginsberg JM, Chang BS, Matarese RA, Garella S Use of single voided urine samples to estimate quantitative pro-teinuria. N Engl J Med 1983, 309(25):1543-1546.
20. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA Expression of transforming growth factor beta is elevated in human and experimental diabetic neph-ropathy. Proc Natl Acad Sci 1993, 90:1814-1818.
21. Ozata M, Kurt I, Azal O, Bolu E, Corakci A, Beyhan Z, et al. Can we use plasma fibronectin levels as a marker for early diabetic nephropathy. Endocrinol J 1995, 42:301-305.
22. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Lenaga K, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic neph-ropathy. Kidney Int 1991, 40:1007-1012.
23. Ishibashi F Glomerular clearance and tubular reabsorption of transferrin in microtransferrinuric patients with non insulin dependent diabetes. Diabetes Res Clin Pract 1994, 25:169-175.
24. Bonner-Weir S, Trent DF, Honey RN, Weir GC Re-sponse to neonatal islets to streptozocin, limited beta cell regeneration and hyperglycemia. Diabetes 1981, 30:64-69.
25. Sharma AK, Srinivasan BP Triple verses glimepiride plus metformin therapy on cardiovascular risk biomark-ers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Euro J Pharm Sci 2009, 38:433-444.
26. Blay M, Peinado-On S, Grasa MM, Diazsilva M, Fernandez-Lopez JA, Remesar X Effect of oral oleoyl-estrone treatment on plasma lipoproteins and tissue li-pase activities of Zuker lean and obese female rats. Int J Obesity 2002, 26(5):618-626.
27. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, et al. Acute effect of glimepiride on insulin stimulated glucose metabolism in glucose-tolerant in-sulin resistant offspring of patients with type 2 diabetes. Diabetes Care 2002, 25:2065-2073.
28. Xu D, Zhao SP, Huang QX, Du W, Lin YH, Lin L, et al. Effects of Glimepiride on metabolic parameters and car-diovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clinical Practice 2010, 88:71-75.
29. Ikeda H, Taketomi S, Sugiyamam Y, Shimura Y, Sohda T, Mequro K, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim-Forsch 1990, 40:156-162.
30. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y Piogli-tazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992, 41(4):476-483.
31. Border WA, Noble NA Interaction of transforming growth factor-β and angiotensin II in renal fibrosis. Hy-pertension 1998, 31:83-97.
32. Wang SN, Hirschberg R Growth factor ultrafiltration in experimental diabetic nephropathy contributes to inter-stitial fibrosis. Am J Physiol Renal Physiol 2000, 278:F554-F560.
33. Parving HH Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998, 41:745-759.
34. DeJong PE, Navis GJ, DeZeeuw D Renoprotective ther-apy: titration against urinary protein excretion. Lancet 1999, 354:352-353.
35. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540-1546.
36. Hasegawa G, Nakano K, Kondo M Role of TNF-α and IL-1 in the development of diabetic nephropathy. Ne-frologia 1995, 15:1-4.
37. Baud L, Fouqueray B, Philippe C, Amram A Tumor necrosis factor α and mesangial cells. Kidney Int 1992, 41:600-603.
38. Egido J, Gómez-Chiari M, Ortiz A, Bustos C, Alonso J, et al. Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. Kidney Int 1993, 43(Suppl 39):S59-S64.